Compound library/Primary-source evidence guide

HGH Fragment 176-191

Human-growth-hormone fragment claims, obesity research context, and product-quality limits

HGH Fragment 176-191 refers to a C-terminal fragment of human growth hormone promoted for fat metabolism. It overlaps conceptually with AOD-9604 discussions, but online claims about targeted fat loss or no endocrine risk require direct human evidence and product-specific quality assurance.

Editorial status

This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .

It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.

Product and regulatory distinctions

A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.

HGH Fragment 176-191 drug products

This guide does not identify a current FDA-approved HGH Fragment 176-191 drug product.

Current source

Compounded fragments

Compounded products are not FDA-approved for safety, effectiveness, or quality before marketing.

Current source

Sport context

Growth-hormone related substances can raise anti-doping issues for covered athletes.

Current source

Claim-by-claim evidence map

Each finding is tied to the population and product actually studied. Trial results are not personal predictions.

Preclinical evidence

An hGH 177-191 fragment showed antilipogenic activity in rat adipose experiments but did not show significant lipolysis in the reported assay.

Population
Peptide-treated rats and epididymal fat-pad assays.
Finding
The study reported antilipogenic activity similar to intact hGH and no significant lipolytic effect measured by glycerol release.
Limits
This animal and tissue work does not establish weight loss, body-composition benefit, dose, or safety in humans and studied residues 177-191 rather than authenticating a marketed product labeled 176-191.
Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone
Preclinical evidence

A C-terminal hGH fragment affected glucose-stimulated insulin release in isolated rat islets.

Population
Isolated rat islets of Langerhans in vitro.
Finding
hGH 177-191 potentiated glucose-induced insulin release in a dose-related manner but did not stimulate insulin release by itself.
Limits
An isolated-cell result cannot establish human metabolic safety or a clinical fat-loss effect.
Effect of synthetic C-terminal fragments of hGH on insulin release by isolated islets
Unsupported or anecdotal

Human AOD-9604 findings cannot be assigned to HGH Fragment 176-191 as though the products were identical.

Population
People comparing gray-market HGH Fragment 176-191 with AOD-9604 development studies.
Finding
FDA describes AOD-9604 as a modified C-terminal hGH fragment with an additional N-terminal tyrosine; the cited human development evidence concerns AOD-9604, not an authenticated HGH Fragment 176-191 product.
Limits
Related sequence and mechanism do not establish product equivalence, human efficacy, or product quality.
AOD-9604: Pharmacy Compounding Advisory Committee briefing document
Unsupported or anecdotal

Product-quality uncertainty is central for online injectable fragments.

Population
People considering online peptide products.
Finding
Identity, concentration, sterility, storage, and impurities are independent quality questions.
Limits
This guide cannot verify a product or seller.
Compounded Drugs: Questions and Answers

What this evidence does not answer

  • No current FDA-approved indication is identified here.
  • Claims of targeted fat loss without endocrine effects need direct controlled evidence.
  • Safety in people with endocrine, cancer, metabolic, or cardiovascular history requires clinician review.

Useful information to organize between visits

  • Exact product label and source
  • Objective body-composition or metabolic measures ordered by a clinician
  • Concurrent weight-loss medicines or hormones
  • Symptoms and injection-site events

Questions to bring to a clinician or pharmacist

  1. 1.What approved therapies fit my metabolic goal?
  2. 2.Is there evidence for this exact product rather than a related fragment?
  3. 3.What endocrine monitoring would be appropriate?

Primary sources

  1. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormoneBiochemistry and Molecular Biology International · Published 1993-05 · Accessed July 12, 2026
  2. Effect of synthetic C-terminal fragments of hGH on insulin release by isolated isletsAmerican Journal of Physiology · Published 1978-05 · Accessed July 12, 2026
  3. AOD-9604: Pharmacy Compounding Advisory Committee briefing documentU.S. Food and Drug Administration · Published 2024 · Accessed July 12, 2026
  4. Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration · Published Current database · Accessed July 12, 2026
  5. Compounded Drugs: Questions and AnswersU.S. Food and Drug Administration · Published Current guidance · Accessed July 12, 2026
  6. 2026 Prohibited ListWorld Anti-Doping Agency · Published 2026 · Accessed July 12, 2026

Turn scattered notes into a useful treatment history

Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.

Start tracking free